Company record · REGN · Pharmaceutical Preparations
Regeneron Pharmaceuticals
The principal financial officer who signed Regeneron Pharmaceuticals's latest annual report, the 10-K filed February 4, 2026, is Christopher Fenimore.
The record holds the CFO signature on Regeneron Pharmaceuticals's 10-K filed February 4, 2026 and no Form 8-K CFO change.
The CFO seat
Computed from the records below: a move filed on or after the 10-K replaces the 10-K's signature.
| Status | Filled |
|---|---|
| Officer | Christopher Fenimore |
| Title as printed | Executive Vice President, Finance and Chief Financial Officer (Principal Financial Officer) |
| Basis | Verified February 4, 2026: the 10-K signature block (sec.gov) |
Seat timeline
1Every verified record for this seat, newest first, dated as the filing states it.
2026-02-0410-K signature
Christopher Fenimore signed the annual report as Executive Vice President, Finance and Chief Financial Officer (Principal Financial Officer)
10-K filed February 4, 2026 · sec.gov
“/s/ CHRISTOPHER FENIMORE Executive Vice President, Finance and Chief Financial Officer (Principal Financial Officer)”
Company
| Ticker | REGN |
|---|---|
| SEC CIK | 0000872589 |
| Industry (SIC) | Pharmaceutical Preparations (2834) |
| Roster note | The DEF 14A filed 2026-04-24 also names Christopher Fenimore alongside a Chief Financial Officer title. |
Same industry on the record
8Other companies the roster files under SIC “Pharmaceutical Preparations”.
Cadrenal Therapeutics, Inc.CVKD
Interim CFO: John P. Sharp · effective June 25, 2026
Petros Pharmaceuticals, Inc.PTPI
Departure disclosed · Robert Weinstein · no successor on the record yet
Actinium Pharmaceuticals, Inc.ATNM
CFO: Matt David, M.D. · effective October 14, 2026
Adial Pharmaceuticals, Inc.ADIL
Departure disclosed · Vinay Shah · no successor on the record yet
BeyondSpring Inc.BYSI
CFO: Na Li · effective July 1, 2026
CalciMedica, Inc.CALC
Departure disclosed · Stephen Bardin · no successor on the record yet
Cue Biopharma, Inc.CUE
CFO: James Ahlers · effective July 30, 2026
Emergent BioSolutions Inc.EBS
Change disclosed, effective January 1, 2027 · incoming: Frank Vargo
This record covers what the tracked filings state; it is not a complete history of the company's finance leadership. Spot an error? Send a correction.